Metsera Announces Positive Phase 1 Results for MET-097, an Ultra-Long-Acting GLP-1 Agonist
In a Phase 1 clinical trial, Metsera’s MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing....
LEO Pharma Unveils Remarkable Results of ANZUPGO® Cream in Chronic Hand Eczema
LEO Pharma presented data at the 33rd European Academy of Dermatology and Venereology (EADV) Congress on the effectiveness and...
City of Hope’s Horizon: City of Hope Gets $20M for Pancreatic Disease Breakthroughs
City of Hope, a leading cancer research and treatment institution, has received a $20 million donation from philanthropists Norman...
Genialis Unveils RNA- and ML-Powered Biomarker for Cancer Treatment Selection
Genialis, a leader in RNA biomarker development, has announced the launch of Genialis krasID, a groundbreaking biomarker capable of...
Pfizer Recalls Worldwide Supplies of Sickle Cell Disease Treatment
Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events...
Investigational Favezelimab and Pembrolizumab Combo Shows Promise in Colorectal Cancer
Merck’s Phase 3 KEYFORM-007 trial tested the efficacy of a fixed-dose combination of favezelimab and pembrolizumab in treating PD-L1-positive...
Merck’s Keytruda® Wins Japan Approval for Advanced Lung and Bladder Cancers
Japan’s Ministry of Health has approved new indications for KEYTRUDA (pembrolizumab) in treating certain lung and urothelial cancers. KEYTRUDA,...
Groundbreaking Zoll Study Enrolls First Patient at Minneapolis Heart Institute
A groundbreaking medical study, the SuperSaturated Oxygen Comprehensive Observational REgistry (SSCORE), has commenced with enrolling its first patient. This...
Trisalus: Improved Tumor Delivery with PEDD™ Method
TriSalus Life Sciences‘ Pressure Enabled Drug Delivery (PEDD) method enhances the delivery of glass microspheres into liver tumors in...
FDA Accepts LEO Pharma’s NDA for Delgocitinib Cream for Chronic Hand Eczema
LEO Pharma has announced the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration...